Debating the Role of AI in Healthcare: The Case of Utah's Doctronic Prescription Refill Program
A new prescription refill program in Utah has sparked a debate about the role of artificial intelligence (AI) in healthcare. The program, called Doctronic, allows residents to refill their prescriptions online through an AI chatbot. While some see this as a convenient advancement, others are concerned about the implications of AI taking on tasks traditionally performed by doctors. Questions have been raised about regulation, safety measures, and the need for AI to meet rigorous standards similar to human doctors.
The program in Utah operates under a regulatory sandbox that allows waivers for AI companies offering innovative technology. A board of AI specialists oversees the program, implementing safeguards such as human doctors reviewing refill orders during the initial phase. However, concerns have been raised about automatically renewing medications without considering potential side effects or drug interactions.
The debate also touches on the jurisdiction of regulating medical technology, which is traditionally overseen at the federal level, while medical professionals are regulated by states. Doctronic executives consider their AI part of state-regulated medicine, but some experts believe the FDA should oversee AI impacting medical care. Despite concerns, Doctronic envisions expanding its services to include routine medical tasks beyond prescription refills.
Other states are also exploring AI in healthcare, with some introducing legislation to license AI medical services. The pushback against medical AI is partly driven by economic fears among healthcare workers. Safety concerns have been raised, particularly regarding the appropriateness of automatically renewing certain medications without considering changes in a patient's medical history.
Utah has provided some initial data on the program, and Doctronic plans to publish peer-reviewed studies later this year. The company conducted a study showing that its AI diagnoses matched those of human doctors 80% of the time. However, experts like Dr. Bressman emphasize the importance of demanding data on prescription refills upfront to ensure patient safety.
The current approach to AI in healthcare is compared to the early 20th-century medical standards, before national benchmarks for training and licensing were established. While the FDA has not authorized any AI chatbots yet, it aims to encourage medical innovation while prioritizing patient safety. As companies like Doctronic expand across states with varying regulatory approaches, there are concerns about compromising public trust and facing backlash in the long run.